Different incidence of interstitial lung disease according to different kinds of EGFR‐tyrosine kinase inhibitors administered immediately before and/or after anti‐PD‐1 antibodies in lung cancer

BACKGROUND: The aim of our study was to retrospectively assess the incidence of interstitial lung disease (ILD) related to EGFR‐tyrosine kinase inhibitor (TKI) treatment immediately before and/or after the administration of a PD‐1 antibody. METHODS: We analyzed the data of 26 patients who underwent...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Thorac Cancer
Glavni autori: Uchida, Takahiro, Kaira, Kyoichi, Yamaguchi, Ou, Mouri, Atsuto, Shiono, Ayako, Miura, Yu, Hashimoto, Kosuke, Nishihara, Fuyumi, Murayama, Yoshitake, Kobayashi, Kunihiko, Kagamu, Hiroshi
Format: Artigo
Jezik:Inglês
Izdano: John Wiley & Sons Australia, Ltd 2019
Teme:
Original Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6449223/
https://ncbi.nlm.nih.gov/pubmed/30864291
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13039
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items